TRIAMCINOLONE ACETONIDE | N020120 | LUPIN ATLANTIS HOLDING SA SWITZERLAND
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 4 | Recruiting | Wake Forest University Health Sciences | 250 | 2018-04-30 → 2027-03 | |
| Phase 3 | Recruiting | University of Washington | 120 | 2013-12 → 2026-07 | |
| Phase 3 | Completed | Shahid Beheshti University of Medical Sciences | — | 2001-06 → 2003-06 | |
| Early Phase 1 | Completed | National Eye Institute (NEI) | 100 | 2006-07 → 2009-07 | |
| Phase 3 | Completed | Novartis Pharmaceuticals | 226 | 2010-03 → 2011-10 | |
| Phase 2 | Completed | Universidade Federal de Goias | 13 | 2008-03 → 2008-10 | |
| N/A | Completed | Yonsei University | 111 | 2012-07 → 2013-04 | |
| N/A | Completed | Taipei Veterans General Hospital, Taiwan | 52 | 2013-04 → 2014-06 | |
| Phase 3 | Completed | Carbylan Therapeutics, Inc. | 510 | 2014-01 → 2016-06 | |
| Phase 3 | Completed | Novartis Pharmaceuticals | 111 | 2005-09 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
12 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Jan 9, 2009 | SUPPL -2 | View Letter (PDF) |
| Feb 4, 2000 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.